ClinicalTrials.gg

Program

lebrikizumab

Also written as “Lebrikizumab”, “lebrikizumab (MILR1444A)” and “LY3650150”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Nasal Polyps · Rhinitis, Allergic, Perennial · Pulmonary Disease, Chronic Obstructive, led by 4 companies.

Furthest: phase 4, since May 28, 202544 company-led studies, 7 open or runningNext primary completion: Apr 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly194 open or runningphase 4since May 28, 2025Feb 16, 2018May 2027phase 3 · NCT06338995
Hoffmann-La Roche180 open or runningphase 3since May 29, 2013Oct 27, 2008none ahead
Almirall63 open or runningphase 3since Nov 26, 2021Nov 26, 2021Apr 25, 2027phase 3 · NCT06526182
Tanox10 open or runningphase 2since May 17, 2006May 17, 2006none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 31 studies since May 17, 2006.

  1. Sep 26, 2022Phase 3 study in Dermatitis, AtopicEli Lilly · NCT05559359 · 377 enrolled · United States, Argentina, Australia and more
  2. Feb 10, 2023Phase 3 study in Dermatitis, AtopicEli Lilly · NCT05735483 · 338 planned · United States, Argentina, Australia and more
  3. May 30, 2023Phase 3 study in Dermatitis, AtopicAlmirall · NCT05916365 · 174 enrolled · Germany, Poland
  4. Aug 7, 2023Phase 3 study in Dermatitis, AtopicAlmirall · NCT05990725 · 260 enrolled · Germany, Netherlands, United Kingdom
  5. Jan 29, 2024Phase 1 study in HealthyEli Lilly · NCT06243198 · 24 enrolled · China
  6. Feb 20, 2024Phase 3 study in Dermatitis, AtopicEli Lilly · NCT06280716 · 301 enrolled · China, South Korea
  7. Mar 25, 20242 phase 3 studiesEli Lilly · NCT06339008, NCT06338995
  8. Jul 24, 2024Phase 3 study in Dermatitis, AtopicAlmirall · NCT06526182 · 520 enrolled · Spain
  9. Apr 4, 2025Phase 3 study in Atopic Hand and Foot DermatitisEli Lilly · NCT06921759 · 221 enrolled · United States, Argentina, Australia and more
  10. May 28, 2025Phase 4 study in Dermatitis, AtopicEli Lilly · NCT07006792 · 233 enrolled · United States, Argentina, Brazil and more
  11. Apr 15, 2026Phase 3 study in DermatitisAlmirall · NCT07542483 · 270 planned · Germany
  12. Oct 8, 2026Phase 3 study in Dermatitis, AtopicAlmirall · NCT07873801 · 230 planned
  13. Oct 27, 2026Primary completion moved from 2026-09 to 2026-10-22Date moved laterphase 3 · +1 months · NCT06339008
  14. Nov 10, 2026Phase 2 study terminatedStudy stoppedNCT01987492 · “Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.”

Ahead

  1. Apr 25, 2027Primary completion: phase 3 study in Dermatitis, AtopicAlmirall · NCT06526182
  2. May 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Eli Lilly · NCT06338995
  3. Dec 2027Primary completion: phase 3 study in Dermatitis, AtopicEli Lilly · NCT05735483
  4. Feb 2028Primary completion: phase 3 study in Dermatitis, AtopicAlmirall · NCT07873801

TargetBeta

IL13 →read by rule
“A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities”NCIt, by rule
“Interleukin-13 inhibitor; Interleukin-13 inhibitor”ChEMBL 37, by rule

Other programs on IL13

ProgramCompanyFurthest phaseStudies
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
zumilokibartAbbViephase 24
ompekimigPfizerphase 23
GHZ339Novartisphase 21
ABBV-313AbbViephase 11

Studies

All 44 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07873801Dermatitis, Atopic3Not yet recruitingAlmirallFeb 2028230
NCT07542483Dermatitis · Germany3RecruitingAlmirallAug 2028270
NCT07006792Dermatitis, Atopic · United States, Argentina, Brazil and more4CompletedEli LillyMay 14, 2026233
NCT06921759Atopic Hand and Foot Dermatitis · United States, Argentina, Australia and more3CompletedEli LillyMay 13, 2026221
NCT06526182Dermatitis, Atopic · Spain3Active, not recruitingAlmirallApr 25, 2027520
NCT06339008Rhinitis, Allergic, Perennial · United States, Belgium, China and more3Active, not recruitingEli LillyOct 22, 2026450
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · United States, Argentina, Belgium and more3RecruitingEli LillyMay 2027510
NCT06280716Dermatitis, Atopic · China, South Korea3CompletedEli LillySep 25, 2025301
NCT06243198Healthy · China1CompletedEli LillySep 3, 202424
NCT05990725Dermatitis, Atopic · Germany, Netherlands, United Kingdom3CompletedAlmirallJun 25, 2025260
NCT05916365Dermatitis, Atopic · Germany, Poland3CompletedAlmirallApr 23, 2026174
NCT05735483Dermatitis, Atopic · United States, Argentina, Australia and more3By invitationEli LillyDec 2027338
NCT05559359Dermatitis, Atopic · United States, Argentina, Australia and more3Active, not recruitingEli LillyJan 14, 2026377
NCT05372419Dermatitis, Atopic · United States3CompletedEli LillyMay 3, 202490
NCT05369403Dermatitis, Atopic · United States3CompletedEli LillyJan 11, 202486
NCT05149313Dermatitis, Atopic · Austria, Belgium, France and more3CompletedAlmirallJan 30, 2023331
NCT04840901Healthy · United States1CompletedEli LillyFeb 11, 2022242
NCT04760314Dermatitis, Atopic · Japan3CompletedEli LillyJul 31, 2022286
NCT04626297Dermatitis, Atopic · United States3CompletedEli LillyAug 3, 2022254
NCT04392154Dermatitis, Atopic · United States, Australia, Bulgaria and more3CompletedEli LillyJul 19, 20241,153
NCT04250350Dermatitis, Atopic · United States, Australia, Canada and more3CompletedEli LillyApr 20, 2022206
NCT04250337Dermatitis, Atopic · United States, Canada, Germany and more3CompletedEli LillyAug 11, 2021228
NCT04178967Dermatitis, Atopic · United States, Bulgaria, Canada and more3CompletedEli LillyJul 12, 2021445
NCT04146363Dermatitis, Atopic · United States, Australia, Canada and more3CompletedEli LillyJun 21, 2021424
NCT03443024Dermatitis, Atopic · United States2CompletedEli LillyFeb 7, 2019280
NCT02546700Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more2CompletedHoffmann-La RocheNov 25, 2016309
NCT02546869Asthma3WithdrawnHoffmann-La RocheJun 29, 20160
NCT02486809Healthy Volunteer · United States1CompletedHoffmann-La RocheOct 2015176
NCT02465606Dermatitis, Atopic · United States, Canada2CompletedHoffmann-La RocheMay 30, 201655
NCT02340234Dermatitis, Atopic · United States, Australia, Canada and more2CompletedHoffmann-La RocheApr 2016212
NCT02104674Asthma · United States, Brazil, Bulgaria and more3CompletedHoffmann-La RocheJan 22, 2016313
NCT02099656Asthma · United States, Canada, France and more2CompletedHoffmann-La RocheOct 13, 201664
NCT01987492Asthma · United States, Australia, Belgium and more2TerminatedHoffmann-La RocheDec 19, 2016230
NCT01875003Asthma · United States, Argentina, Brazil and more3TerminatedHoffmann-La RocheDec 28, 2016346
NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more2CompletedHoffmann-La RocheJul 28, 2017505
NCT01868061Asthma · United States, Argentina, Australia and more3CompletedHoffmann-La RocheJan 2, 20171,068
NCT01867125Asthma · United States, Argentina, Australia and more3CompletedHoffmann-La RocheDec 28, 20161,081
NCT01545453Asthma · United States, Australia2CompletedHoffmann-La RocheJul 2013205
NCT01545440Asthma · United States, Australia2CompletedHoffmann-La RocheMar 2013258
NCT01423318Healthy Volunteer · United States1CompletedHoffmann-La RocheFeb 201260
NCT00971035Asthma2CompletedHoffmann-La RocheDec 2010210
NCT00930163Asthma2CompletedHoffmann-La RocheJul 2010218
NCT00781443Asthma2CompletedHoffmann-La RocheNov 200929
NCT00441818Hodgkin Disease · United States2UNKNOWNTanox59

How it is read

Names in the registry

  • “Lebrikizumab”, 37 entries
  • “lebrikizumab”, 7 entries
  • “lebrikizumab (MILR1444A)”, 5 entries
  • “LY3650150”, 2 entries
  • “TNX-650”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.